Timothy A. Chan
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 101
- Cancer Immunotherapy and Biomarkers 59
- Lung Cancer Research Studies 17
- CAR-T cell therapy research 17
-
- Brain Metastases and Treatment 31
- Renal cell carcinoma treatment 17
- Co-authors
- Jonathan J. Havel (8 shared papers)Diego Chowell (13 shared papers)Kenneth W. Kinzler (6 shared papers)Bert Vogelstein (6 shared papers)Luc G.T. Morris (30 shared papers)Nadeem Riaz (24 shared papers)Solange Peters (1 shared paper)Sergio A. Quezada (1 shared paper)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (27 papers)Journal of Clinical Oncology (21 papers)Clinical Cancer Research (13 papers)Oncotarget (9 papers)Cancer Research (8 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Timothy A. Chan
234 papers receiving 23.0k citations
Timothy A. Chan's Hit Papers
Peers
Comparison fields: 5 of 161
- Oncology 8.7k
- Cancer Research 4.2k
- Genetics 2.2k
- Immunology 4.1k
- Pulmonary and Respiratory Medicine 4.4k
Countries citing papers authored by Timothy A. Chan
This map shows the geographic impact of Timothy A. Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy A. Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy A. Chan more than expected).
Fields of papers citing papers by Timothy A. Chan
This network shows the impact of papers produced by Timothy A. Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy A. Chan. The network helps show where Timothy A. Chan may publish in the future.
Co-authors
The 25 scholars most cited alongside Timothy A. Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 243 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic Hit paper breakdown → | 2018 | 1878 |
| 2 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Hit paper breakdown → | 2019 | 1630 |
| 3 | IDH mutation impairs histone demethylation and results in a block to cell differentiation Hit paper breakdown → | 2012 | 1465 |
| 4 | PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs Hit paper breakdown → | 1999 | 915 |
| 5 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 767 |
| 6 | 14-3-3σ is required to prevent mitotic catastrophe after DNA damage Hit paper breakdown → | 1999 | 740 |
| 7 | The head and neck cancer immune landscape and its immunotherapeutic implications Hit paper breakdown → | 2016 | 562 |
| 8 | Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis Hit paper breakdown → | 1998 | 503 |
| 9 | Genome Sequencing Identifies a Basis for Everolimus Sensitivity Hit paper breakdown → | 2012 | 481 |
| 10 | A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 455 |
| 11 | The hallmarks of successful anticancer immunotherapy Hit paper breakdown → | 2018 | 407 |
| 12 | 2000 | 386 | |
| 13 | 2001 | 355 | |
| 14 | Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease Hit paper breakdown → | 2013 | 344 |
| 15 | Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment Hit paper breakdown → | 2015 | 310 |
| 16 | High-Resolution, Small Animal Radiation Research Platform With X-Ray Tomographic Guidance Capabilities Hit paper breakdown → | 2008 | 307 |
| 17 | 2015 | 268 | |
| 18 | COVID-19 and Cardiovascular Disease Hit paper breakdown → | 2021 | 256 |
| 19 | The hallmarks of cancer immune evasion Hit paper breakdown → | 2024 | 254 |
| 20 | 2017 | 241 |
About Timothy A. Chan
Timothy A. Chan is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Genetics, having authored 243 papers that have together received 23.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (59 papers), Glioma Diagnosis and Treatment (37 papers), Brain Metastases and Treatment (31 papers), Immunotherapy and Immune Responses (27 papers), Cancer Genomics and Diagnostics (25 papers), Renal cell carcinoma treatment (17 papers), Lung Cancer Research Studies (17 papers) and CAR-T cell therapy research (17 papers). The work is most often cited by research in Oncology (8.7k citations), Cancer Research (4.2k citations), Genetics (2.2k citations), Immunology (4.1k citations) and Pulmonary and Respiratory Medicine (4.4k citations). Timothy A. Chan has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Jonathan J. Havel, Diego Chowell, Kenneth W. Kinzler, Bert Vogelstein, Luc G.T. Morris, Nadeem Riaz, Solange Peters, Sergio A. Quezada, Mark Yarchoan and Charles Swanton. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Journal of Clinical Oncology, Clinical Cancer Research, Oncotarget and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.